Evaluation of permissiveness and cytotoxic effects in equine chondrocytes, synovial cells, and stem cells in response to infection with adenovirus 5 vectors for gene delivery

American Journal of Veterinary Research

Volumn 67, Issue 7, 2006, Pages 1145-1155

  Ishihara, Akikazu ^a   Zachos, Terri A ^a   Bartlett, Jeffrey S ^b,c   Bertone, Alicia L ^a,c  

^a Department of Veterinary Biosciences   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; BETA GALACTOSIDASE; GREEN FLUORESCENT PROTEIN;

ADENOVIRUS 5; ANIMAL CELL; ARTICLE; ARTICULAR CARTILAGE; BONE MARROW; CARTILAGE CELL; CELL COUNT; CELL CULTURE; CELL STRUCTURE; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HELA CELL; HORSE; HOST CELL; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; NONHUMAN; SYNOVIOCYTE; SYNOVIUM; TARGET CELL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BONE MARROW CELLS; CHONDROCYTES; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HORSES; HUMANS; STEM CELLS; SYNOVIAL MEMBRANE;

ADENOVIRIDAE; EQUIDAE; HUMAN ADENOVIRUS TYPE 5; HUMAN ECHOVIRUS 1; MIRIDAE;

EID: 33747590181     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.7.1145     Document Type: Article

References (69)

1. Baltzer AW, Lattermann C, Whalen JD, et al. A gene therapy approach to accelerating bone healing. Evaluation of gene expression in a New Zealand white rabbit model. Knee Surg Sports Traumatol Arthrosc 1999;7:197-202.
2. Oakes DA, Lieberman JR. Osteoinductive applications of regional gene therapy: ex vivo gene transfer. Clin Orthop 2000;379:S101-S112.
3. Baltzer AW, Lattermann C, Whalen JD, et al. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther 2000;11:734-739.
4. Lieberman JR, Ghivizzani SC, Evans CH. Gene transfer approaches to the healing of bone and cartilage. Mol Ther 2002;6:141-147.
5. Baltzer AW, Lattermann C. Regional gene therapy to enhance bone repair. Gene Ther 2004;11:344-350.
6. McKay B, Sandhu HS. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 2002;27:S66-S85.
7. Vaccaro AR, Anderson DG, Toth CA. Recombinant human osteogenic protein-1 (bone morphogenetic protein-7) as an osteoinductive agent in spinal fusion. Spine 2002;27:S59-S65.
8. Suh DY, Boden SD, Louis-Ugbo J, et al. Delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2) using a compression resistant matrix in posterolateral spine fusion in the rabbit and non-human primate. Spine 2002;27:353-360.
9. Dumont RJ, Dayoub H, Li JZ, et al. Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents. Neurosurgery 2002;51:1239-1244.
10. Yoon ST, Boden SD. Spine fusion by gene therapy. Gene Ther 2004;11:360-367.
11. Kang R, Marui T, Ghivizzani SC, et al. Ex vivo gene transfer to chondrocytes in full-thickness articular cartilage defects: a feasibility study. Osteoarthritis Cartilage 1997;5:139-143.
12. Pelletier JP, Caron JP, Evans C, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997;40:1012-1019.
13. Fernandes J, Tardif G, Martel-Pelletier J, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999;154:1159-1169.
14. Ikeda T, Kubo T, Nakanishi T, et al. Ex vivo gene delivery using an adenovirus vector in treatment for cartilage defects. J Rheumatol 2000;27:990-996.
15. Evans CH, Ghivizzani SC, Smith P, et al. Using gene therapy to protect and restore cartilage. Clin Orthop Relat Res 2000; suppl 379:S214-S219.
16. Brower-Toland BD, Saxer RA, Goodrich LR, et al. Direct adenovirus-mediated insulin-like growth factor I gene transfer enhances transplant chondrocyte function. Hum Gene Ther 2001; 12:117-129.
17. Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for arthritis. Gene Ther 2003;10:902-911.
18. Evans CH, Gouze JN, Gouze F, et al. Osteoarthritis gene therapy. Gene Ther 2004;11:379-389.
19. Frisbie DD, Ghivizzani SC, Robbins PD, et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002;9:12-20.
20. Goossens PH. Infection efficacy of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber. Arthritis Rheum 2001;44:570-577.
21. Goodrich LR. Long-term biochemical analysis of articular cartilage repaired with genetically modified chondrocytes expressing insulin-like growth factor-1. Vet Surg 2003;32:1-2.
22. Hirschmann F, Verhoeyen E, Wirth D, et al. Vital marking of articular chondrocytes by retroviral infection using green fluorescence protein. Osteoarthritis Cartilage 2002;10:109-118.
23. Daga A, Muraglia A, Quarto R, et al. Enhanced engraftment of EPO-transduced human bone marrow stromal cells transplanted in a 3D matrix in non-conditioned NOD/SCID mice. Gene Ther 2002;9:915-921.
24. Tew SR, Li Y, Pothacharoen P, et al. Retroviral transduction with SOX9 enhances re-expression of the chondrocyte phenotype in passaged osteoarthritic human articular chondrocytes. Osteoarthritis Cartilage 2005;13:80-89.
25. Hidaka C, Goodrich LR, Chen CT, et al. Acceleration of cartilage repair by genetically modified chondrocytes overexpressing bone morphogenetic protein-7. J Orthop Res 2003;21:573-583.
26. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, et al. Efficient gene transfer into human CD34+ cells by a retargeted adenovirus vector. J Virol 2000;74:2567-2583.
27. Kimura E, Maeda Y, Arima T, et al. Efficient repetitive gene delivery to skeletal muscle using recombinant adenovinus vector containing the coxsackievirus and adenovirus receptor cDNA. Gene Then 2001;8:20-27.
28. Yun CO, Cho EA, Song JJ, et al. dl-VSVG-LacZ, a vesicular stomatitis virus glycoprotein epitope-incorporated adenovirus, exhibits marked enhancement in gene transduction efficiency. Hum Gene Ther 2003;14:1643-1652.
29. Rivera AA, Davydova J, Schierer S, et al. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther 2001;11:1694-1702.
30. Ogawara K, Rots MG, Kok RJ, et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 2004;15:433-443.
31. Goldman M, Su Q, Wilson JM. Gradient of RGD-dependent entry of adenoviral vector in nasal and intrapulmonary epithelia: implications for gene therapy of cystic fibrosis. Gene Ther 1996;3:811-818.
32. Bregni M, Shammah S, Malaffo F, et al. Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. Gene Ther 1998;5:465-472.
33. Gafni Y, Turgeman G, Liebergal M, et al. Stem cells as vehicles for orthopedic gene therapy. Gene Ther 2004;11:417-426.
34. Lieberman JR, Daluiski A, Stevenson S, et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Sung Am 1999;81:905-917.
35. Gazit D, Turgeman G, Kelley P et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J Gene Med 1999;1:121-133.
36. Olmsted-Davis EA, Gugala Z, Gannon FH, et al. Use of a chimeric adenovirus vector enhances BMP2 production and bone formation. Hum Gene Ther 2002;13:1337-1347.
37. Peterson B, Wang J, Zhang J, et al. Genetically modified human derived bone marrow cells for posterolateral lumbar spine fusion via gene therapy. Trans ORS 2003;28:425.
38. Gugala Z, Olmsted-Davis EA, Gannon FH, et al. Osteoinduction by ex vivo adenovirus-mediated BMP2 delivery is independent of cell type. Gene Ther 2003;10:1289-1296.
39. Pascher A, Palmer GD, Steinert A, et al. Gene delivery to cartilage defect using coagulated bone marrow aspirate. Gene Ther 2004;11:133-141.
40. Lieberman JR Le LQ, Wu L, et al. Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 1998;16:330-339.
41. Lou J, Xu F, Merkel K, et al. Gene therapy: adenovirus-mediated human bone morphogenetic protein-2 gene transfer induces mesenchymal progenitor cell proliferation and differentiation in vitro and bone formation in vivo. J Orthop Res 1999;17:43-50.
42. Engstrand T, Daluiski A, Bahamonde ME, et al. Transient production of bone morphogenetic protein 2 by allogeneic transplanted transduced cells induces bone formation. Hum Gene Ther 2000;11:205-211.
43. Gysin R, Wergedal JE, Sheng MH, et al. Ex vivo gene therapy with stromal cells transduced with a retroviral vector containing the BMP4 gene completely heals. Gene Ther 2002;9:991-999.
44. Wright V, Peng H, Usas A, et al. BMP4-expressing muscle-derived stem cells differentiate into osteogenic lineage and improve bone healing in immunocompetent mice. Mol Ther 2002;6:169-178.
45. Peng H, Wright V, Usas A, et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VFGF and bone morphogenetic protein-4. J Clin Invest 2002;110:751-759.
46. Fortier LA, Nixon AJ, Williams J, et al. Isolation and chondrocytic differentiation of equine bone marrow-derived mesenchymal stem cells. Am J Vet Res 1998;59:1182-1187.
47. Von Seegern DJ, Huang S, Felck SK, et al. Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol 2000;74:354-362.
48. Printz MA, Gonzalez AM, Cunningham M, et al. Fibroblast growth factor 2-related adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum Gene Ther 2000;11:191-204.
49. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovinus receptor-independent cell entry mechanism. J Virol 1998;72:9706-9731.
50. Liu Y, Ye T, Sun D, et al. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma. Hum Gene Ther 2004;15:637-647.
51. Caron JP, Tardif G, Martel-Pelletier J, et al. Modulation of matrix metalloprotease 13 (collagenase 3) gene expression in equine chondrocytes by interleukin 1 and corticosteroids. Am J Vet Res 1996;57:1631-1634.
52. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2004;6:S152-S163.
53. Medina-Kauwe LK. Endocytosis of adenovirus and adenovirus capsid proteins. Adv Drug Deliv Rev 2003;55:1485-1496.
54. Bertone AL, Gu W, Shi W, et al. RGD modified adeno-associated virus type 2 (AAV2) vector provides expanded tropism to articular cells. In: The 32nd annual Mallory Coleman research day. Columbus, Ohio: The Ohio State University, 2004;8-10.
55. Girod A, Ried M, Wobus C, et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999;5:1052-1056.
56. Shi W, Bartlett JS. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 2003;7:515-525.
57. Yokoo N, Saito T, Uesugi M, et al. Repair of articular cartilage defect by autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector. Arthritis Rheum 2005;52:164-170.
58. Ulrich-Vinther M, Duch MR, Soballe K, et al. In vivo gene delivery to articular chondrocytes mediated by an adeno-associated virus vector. J Orthop Res 2004;22:726-734.
59. Bruder SP, Jaiswal N, Ricalton NS, et al. Mesenchymal stem cells in osteobiology and applied bone regeneration. Clin Orthop Relat Res 1998; suppl 355:S247-S256.
60. Bruder SP, Kurth AA, Shea M, et al. Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. J Orthop Res 1998;16:155-162.
61. Bakker AC, Loo FAJ, Joosten LAB, et al. A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis. Gene Ther 2001;8:1785-1793.
62. Ikeda T, Kubo T, Arai Y, et al. Adenovirus mediated gene delivery to the joints of guinea pigs. J Rheumatol 1998;25:1666-1673.
63. Evans CH, Gouze JN, Gouze E, et al. Osteoarthritis gene therapy. Gene Ther 2004;11:379-389.
64. Bandara G, Robbins PD, Georgescu HI, et al. Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol 1992;11:227-231.
65. Bandara G, Mueller GM, Galea-Lauri J, et al. Intraarticular expression of biologically active interleukin-1 receptor antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 1993;90:10764-10768.
66. Nita I, Ghivizzani SC, Galea-Lauri J, et al. Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996;39:820-828.
67. Oligino TJ, Yao Q, Ghivizzani SC, et al. Vector systems for gene transfer to joints. Clin Orthop Relat Res 2000; suppl 379:S17-S30.
68. Evans CH, Ghivizzani SC, Kang R, et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999;42:1-16.
69. Bertone AL, Pittman DD, Bouxsein ML, et al. Adenoviral-mediated transfer of human BMP-6 gene accelerates healing in a rabbit ulnar osteotomy model. J Orthop Res 2004;22:1261-1270.